{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T20:06:40Z","timestamp":1774123600545,"version":"3.50.1"},"reference-count":22,"publisher":"SAGE Publications","issue":"2","license":[{"start":{"date-parts":[[2009,4,1]],"date-time":"2009-04-01T00:00:00Z","timestamp":1238544000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Ther Adv Respir Dis"],"published-print":{"date-parts":[[2009,4]]},"abstract":"<jats:p> Background: Several studies suggest that inhaled and oral corticosteroids repress systemic inflammation in chronic obstructive pulmonary disease (COPD). However, the cytokines that may respond to these medications are unclear. <\/jats:p><jats:p> Method: We used data from 41 patients with a history of stable moderate COPD (average age 64 years) who were randomised to inhaled fluticasone (500 \u03bcg twice daily from a Diskus inhaler), oral prednisone (30 mg daily) or placebo for 2 weeks. Using a multiplexed array system, different serum cytokines that have been implicated in COPD pathogenesis were measured. <\/jats:p><jats:p> Results: We found that compared with placebo, inhaled fluticasone significantly reduced levels of soluble tumour necrosis factor receptor-2 (sTNF-R2) by 24% (95% CI, 7\u201438%; p = 0.01), monocyte chemoattractant protein-1 by 20% (95% CI, 5\u201432%; p = 0.01), interferon gamma inducible CXCL10 (IP-10) by 43% (95% CI, 3\u201466%; p = 0.04), and soluble L-selectin levels by 15% (95% CI, 1\u201428%; p = 0.04). Compared with placebo, oral prednisone reduced levels of sTNF-R2 by 26% (95% CI, 15\u201436%; p &lt; 0.001), L-selectin by 22% (95% CI, 8\u201434%; p = 0.004), intercellular adhesion molecule-1 by 31% (95% CI, 9\u201448%; p = 0.01), pulmonary and activation-regulated chemokine (PARC) by 18% (95% CI, 2\u201432%; p = 0.03) and IP-10 by 40% (95% CI, 0\u201464%; p = 0.05). sTNF-R2, L-selectin and IP-10 were significantly reduced by both oral and inhaled corticosteroids. The other cytokines were not significantly repressed by either oral or inhaled corticosteroids. <\/jats:p><jats:p> Conclusions: In summary, inhaled and oral corticosteroids significantly repressed a selected number of systemic cytokines in patients with stable, moderate COPD; most of the steroid-responsive cytokines appear to be chemoattractants. <\/jats:p>","DOI":"10.1177\/1753465809336697","type":"journal-article","created":{"date-parts":[[2009,5,23]],"date-time":"2009-05-23T00:36:12Z","timestamp":1243038972000},"page":"73-80","source":"Crossref","is-referenced-by-count":18,"title":["The effects of inhaled and oral corticosteroids on serum inflammatory biomarkers in COPD: an exploratory study"],"prefix":"10.1177","volume":"3","author":[{"given":"S.F. Paul","family":"Man","sequence":"first","affiliation":[{"name":"Department of Medicine (Respiratory Division), University of British Columbia and the Providence Heart and Lung Institute at St. Paul's Hospital (James Hogg iCAPTURE Center), Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Xuekui Zhang","sequence":"additional","affiliation":[{"name":"Department of Medicine (Respiratory Division), University of British Columbia and the Providence Heart and Lung Institute at St. Paul's Hospital (James Hogg iCAPTURE Center), Vancouver, BC, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rupert","family":"Vessey","sequence":"additional","affiliation":[{"name":"Discovery Medicine, High Throughput Biology and Data Exploration Sciences, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Terry","family":"Walker","sequence":"additional","affiliation":[{"name":"Discovery Medicine, High Throughput Biology and Data Exploration Sciences, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwan","family":"Lee","sequence":"additional","affiliation":[{"name":"Discovery Medicine, High Throughput Biology and Data Exploration Sciences, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Park","sequence":"additional","affiliation":[{"name":"Discovery Medicine, High Throughput Biology and Data Exploration Sciences, GlaxoSmithKline R&D, King of Prussia, Pennsylvania, US"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don D.","family":"Sin","sequence":"additional","affiliation":[{"name":"Department of Medicine (Respiratory Division), University of British Columbia and the Providence Heart and Lung Institute at St. Paul's Hospital (James Hogg iCAPTURE Center), Vancouver, BC, Canada,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2009,5,22]]},"reference":[{"key":"atypb1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200508-1321OC"},{"key":"atypb2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00040703"},{"key":"atypb3","doi-asserted-by":"publisher","DOI":"10.1016\/S0895-4356(00)00314-0"},{"key":"atypb4","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9150(03)00097-2"},{"key":"atypb5","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.320.7245.1297"},{"key":"atypb6","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2003.019588"},{"key":"atypb7","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.05.00079004"},{"key":"atypb8","doi-asserted-by":"publisher","DOI":"10.1001\/jama.294.10.1255"},{"key":"atypb9","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/37.3.282"},{"key":"atypb10","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200205-446OC"},{"key":"atypb11","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00128806"},{"key":"atypb12","doi-asserted-by":"publisher","DOI":"10.1378\/chest.130.3.640"},{"key":"atypb13","doi-asserted-by":"publisher","DOI":"10.1016\/S0091-6749(99)70107-7"},{"key":"atypb14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa040967"},{"key":"atypb15","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200608-1125OC"},{"key":"atypb16","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(04)16855-4"},{"key":"atypb17","doi-asserted-by":"publisher","DOI":"10.1136\/thx.2006.064428"},{"key":"atypb18","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4530(00)00039-1"},{"key":"atypb19","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.28.6.1376"},{"key":"atypb20","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-543OC"},{"key":"atypb21","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000056767.69054.B3"},{"key":"atypb22","first-page":"414","volume":"11","author":"Stoeck, M.","year":"2000","journal-title":"Eur Cytokine Netw"}],"container-title":["Therapeutic Advances in Respiratory Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753465809336697","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/1753465809336697","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,3]],"date-time":"2025-03-03T23:13:51Z","timestamp":1741043631000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/1753465809336697"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2009,4]]}},"alternative-id":["10.1177\/1753465809336697"],"URL":"https:\/\/doi.org\/10.1177\/1753465809336697","relation":{},"ISSN":["1753-4666","1753-4666"],"issn-type":[{"value":"1753-4666","type":"print"},{"value":"1753-4666","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,4]]}}}